Literature DB >> 26377250

Bullous Sweet's Syndrome: Report of an Atypical Case Presenting with Ring-Like, Figurate Lesions.

Andaç Salman1, Aida Berenjian, Ali Eser, Fatma Dilek Kaymakçı, Leyla Cinel, Işık Kaygusuz Atagündüz, Deniz Yücelten, Tülin Ergun.   

Abstract

Entities:  

Year:  2015        PMID: 26377250      PMCID: PMC5451680          DOI: 10.4274/tjh.2015.0202

Source DB:  PubMed          Journal:  Turk J Haematol        ISSN: 1300-7777            Impact factor:   1.831


× No keyword cloud information.
A 68-year-old woman presented with a 2-month history of erythematous, blistering lesions refractory to systemic antibiotic treatment. Her medical history was insignificant except for long-standing diabetes mellitus, hepatitis C infection, and recently diagnosed myelodysplastic syndrome, refractory anemia with excess blasts-1 (MDS-RAEB-1). She denied any recent intake of drugs prior to the onset of skin lesions. Dermatological examination revealed widespread, erythematous, concentric, circinate large plaques with peripheral bullae formation over the trunk and extremities (Figures 1A and 1B). Laboratory tests disclosed leukocytosis (32x109/L) with neutrophilia (7.2x109/L), anemia (hemoglobin: 76 g/L), thrombocytopenia (16x109/L), elevated levels of C-reactive protein (1133.36 nmol/L) and erythrocyte sedimentation rate (111 mm/h), normal levels of aspartate aminotransferase (0.17 µkat/L) and alanine aminotransferase (0.22 µkat/L), and hepatitis C virus-ribonucleic acid (HCV-RNA) negativity. A punch biopsy was obtained with a differential diagnosis of bullous Sweet’s syndrome (SS) and erythema gyratum repens. Histopathology showed diffuse, dermal inflammatory infiltrate rich in neutrophils with subepidermal blister formation (Figure 2). Clinical and laboratory findings confirmed the diagnosis of bullous SS associated with MDS-RAEB-1. In addition to topical corticosteroids and oral colchicine, treatment with azacitidine led to rapid resolution of the lesions. There was no recurrence of SS until the patient’s death before the second azacitidine cycle.
Figure 1

Widespread, erythematous, ring-like plaques with peripheral blisters on the trunk (A and B).

Figure 2

Dermal infiltrate rich in neutrophils with subepidermal blister formation (H&E, 20x).

SS is characterized by erythematous, tender plaques and papules involving the head, neck, and upper extremities [1,2]. It may be associated with infections, hematologic malignancies, inflammatory bowel disease, and drugs [2]. SS may also be associated with chronic active hepatitis; however, normal liver function tests, HCV-RNA negativity, and the temporal relationship between skin lesions and hematological findings in our case make this unlikely. Although pseudovesicular appearance due to severe edema can be seen in SS, bullae formation with figurate and ring-like lesions is rare [3,4,5]. Figurate lesions without bullae in SS were previously reported in a patient with no associated disease [3]. In conclusion, the diagnosis of SS should be kept in mind in patients with erythema gyratum repens-like or concentric blistering lesions.
  5 in total

1.  Sweet's syndrome masquerading as figurate erythema.

Authors:  Barbara Behm; Stephan Schreml; Michael Landthaler; Philipp Babilas
Journal:  Int J Dermatol       Date:  2012-02-09       Impact factor: 2.736

2.  Bullous variant of Sweet's syndrome.

Authors:  Susanne Voelter-Mahlknecht; Jürgen Bauer; Gisela Metzler; Gerhard Fierlbeck; Gernot Rassner
Journal:  Int J Dermatol       Date:  2005-11       Impact factor: 2.736

3.  Sweet's syndrome: a spectrum of unusual clinical presentations and associations.

Authors:  C Y Neoh; A W H Tan; S K Ng
Journal:  Br J Dermatol       Date:  2007-03       Impact factor: 9.302

Review 4.  Sweet's syndrome: a revisit for hematologists and oncologists.

Authors:  Semra Paydas
Journal:  Crit Rev Oncol Hematol       Date:  2012-10-07       Impact factor: 6.312

Review 5.  Acute febrile neutrophilic dermatosis (Sweet's syndrome).

Authors:  Charles L Anzalone; Philip R Cohen
Journal:  Curr Opin Hematol       Date:  2013-01       Impact factor: 3.284

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.